Proceed with Surgery and Continue Current Medications
In this 68-year-old woman with a preoperative blood pressure of 178/104 mm Hg, the most appropriate management is to administer oral antihypertensive medication and proceed with surgery (Option 3). Her blood pressure does not meet the threshold for mandatory surgical delay, she is asymptomatic, and canceling surgery would expose her to unnecessary risk without proven benefit.
Rationale Based on Current Guidelines
Blood Pressure Threshold Analysis
The 2017 ACC/AHA guidelines provide clear direction: deferring surgery may be considered only when SBP ≥180 mm Hg or DBP ≥110 mm Hg 1, 2, 3. This patient's BP of 178/104 mm Hg falls just below both thresholds. The 2025 ACC/AHA guideline reinforces that patients with preoperative SBP/DBP <180/110 mm Hg can proceed with surgery, as there is little evidence of increased perioperative complications below these values 4.
The British guidelines from 2016 support an even more permissive approach, recommending proceeding with surgery when BP is <180/110 mm Hg measured in the preoperative clinic 5. This patient's 178/104 mm Hg reading aligns with proceeding safely.
Why Not Cancel Surgery (Option 1)
Canceling surgery for outpatient blood pressure management is not supported by evidence at this BP level. The landmark Weksler study of 989 hypertensive patients with DBP 110-130 mm Hg found no statistically significant differences in postoperative complications between those who had surgery postponed for BP control versus those who proceeded 6, 7. This patient's DBP of 104 mm Hg is actually lower than the study population, making cancellation even less justified.
Why Not IV Labetalol with Rescheduling (Option 2)
Rescheduling after IV antihypertensive administration is unnecessarily disruptive. While IV agents can control BP within hours 6, there is no evidence that acute BP reduction immediately before surgery improves outcomes when BP is <180/110 mm Hg. The 2024 perioperative guideline notes that deferring surgery should only be considered in patients with "recent history of poorly controlled hypertension" and cardiovascular risk factors undergoing elevated-risk surgery 8—but this is a "may be considered" (Class IIb) recommendation, not a mandate.
The Correct Approach: Oral Medication and Proceed (Option 3)
It is reasonable to continue medical therapy for hypertension until surgery (Class IIa recommendation) 1, 2, 3. This patient should:
- Continue her metoprolol (Class I recommendation—beta blockers must be continued in patients chronically taking them) 1, 2, 3, 4
- Consider holding lisinopril the morning of surgery (Class IIb recommendation—ACE inhibitors may be discontinued perioperatively due to increased risk of intraoperative hypotension) 1, 2, 3, 8
- Administer additional oral antihypertensive medication to bring BP closer to target before proceeding
The rationale for holding ACE inhibitors is critical: patients taking ACE inhibitors are more likely to develop intraoperative hypotension 6, 7, and the FDA label for lisinopril specifically warns that it "may block angiotensin II formation secondary to compensatory renin release" during surgery, potentially causing hypotension 9. With her stage 3 CKD (creatinine 1.5), she's at particular risk for hemodynamic instability.
Why Not Just Increase Metoprolol (Option 4)
Simply increasing metoprolol dose without addressing the ACE inhibitor issue misses a key perioperative management principle. Beta blockers should be continued at their current dose (Class I) 1, 2, 3, but beta blockers should not be started or significantly uptitrated on the day of surgery in patients not already on optimal doses (Class III: Harm) 1, 2, 3. The FDA label for metoprolol emphasizes initiating at low doses with cautious titration 10.
Critical Perioperative Considerations
Abrupt Discontinuation is Harmful
Abruptly stopping metoprolol is potentially harmful (Class III: Harm) 1, 2, 3, 4. Beta blocker withdrawal can cause rebound hypertension and increased cardiovascular events. This patient must continue her metoprolol throughout the perioperative period.
Intraoperative Management Plan
Once surgery proceeds, intraoperative hypertension should be managed with IV medications (Class I recommendation) 1, 2, 3. Maintain MAP ≥60-65 mm Hg or SBP ≥90 mm Hg to reduce myocardial injury risk 8. Her chronic hypertension means she may require higher BP targets than younger patients.
Postoperative Restart Strategy
Restart antihypertensive medications as soon as clinically reasonable postoperatively (Class I recommendation) 8. For lisinopril specifically, restart only after she is euvolemic to decrease perioperative renal dysfunction risk 6, 7—particularly important given her baseline CKD and creatinine of 1.5.
Common Pitfalls to Avoid
- Do not cancel surgery for BP 178/104 mm Hg—this delays necessary care without evidence of benefit
- Do not abruptly stop beta blockers—this causes rebound hypertension and increases cardiovascular risk
- Do not continue ACE inhibitors the morning of surgery—this increases intraoperative hypotension risk, especially with CKD
- Do not start new beta blockers or significantly increase doses on the day of surgery—this increases mortality risk
- Do not forget to assess volume status—hypovolemia combined with ACE inhibitors dramatically increases hypotension risk